Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-05-23
2010-06-15
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07737180
ABSTRACT:
Use of neboglamine, (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), of the racemate thereof or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of schizophrenia.
REFERENCES:
patent: 3665037 (1972-05-01), Murakami et al.
patent: WO 9420454 (1994-09-01), None
patent: WO 03045913 (2003-05-01), None
Flint et al. A qualitative analysis of the negative symptoms of schizophrenia interfering with academic and social success, and the exacerbators and diminishers of those symptoms. Dissertation Abstracts International, 2003 vol. 64, No. 12A. p. 4420. Abstract.
Garofalo et al. CR 2249: a New putative memory enhnacer. Behavioural studies on learning and memory in rats and mice. J. Pharm. Pharmacol. 1996, 48, pp. 1290-1297.
Victor Peralta, Are There More Than Two Syndromes in Schizophrenia? A Critique of the Positive-Negative Dichotomy, British Journal of Psychiatry (1992), 161, 335-343.
R.D. Porsolt, Behavioural Despair in Mice: A Primary Screening Test for Antidepressants, Arch. int. Pharmacodyn. 229, 327-336 (1977).
N. R. Swerdlow, Effects of Spiperone, Raclopride, SCH 23390 and Clozapine on Apomorphine Inhibition of Sensorimotor Gating of the Startle Response in the Rat, The Journal of Pharmacology and Experimental Therapeutics, vol. 256, No. 2, U.S.
J. David Jentsch, The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia, Neurospychopharmacology, 1999-vol. 20, No. 3.
Paolo Garofalo, CR 2249: a New Putative Memory Enhancer. Behavioural Studies on Learning and Memory in Rats and Mice, J. Pharm. Pharmacol. 1996, 48: 1290-1297, Feb. 27, 1996.
M. Lanza, Characteriztion of a Novel Putative Cognition Enhancer Mediting Facilittion of Glycine Effect on Strychnine-Resistant Sites Coupled to NMDA Receptor Complex, Neuropharmacology, vol. 26, No. 8, pp. 1057-1064, 1997.
Yousry Sayed, The Dopamine Hypothesis of Schizophrenia and the Antagonistic Action of Neuoleptic Drugs—A Review; The British Library, vol. 19, No. 2, 1983.
Nancy C. Andreasen, Methods for Assessing Positive and Negative Symptoms, Department of Psychiatry, University of Iowa College of Medicine, 1990, vo. 24, pp. 73-88.
Makovec Francesco
Rovati Lucio Claudio
Kim Jennifer M
Rottapharm S.p.A.
Roylance Abrams Berdo & Goodman L.L.P.
LandOfFree
Use of neboglamine (CR 2249) as an antipsychotic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of neboglamine (CR 2249) as an antipsychotic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of neboglamine (CR 2249) as an antipsychotic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201266